- |||||||||| LY3509754 / Eli Lilly
Trial termination: A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants (clinicaltrials.gov) - Dec 21, 2022
P1, N=104, Terminated,
In conclusion, despite strong target engagement and a PK profile that supported once-daily administration, this study showed that oral dosing with LY3509754 was poorly tolerated. Suspended --> Terminated; Terminated due to safety findings
- |||||||||| LY3509754 / Eli Lilly
Trial completion date, Trial primary completion date: A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants (clinicaltrials.gov) - Sep 13, 2022
P1, N=105, Suspended,
Suspended --> Terminated; Terminated due to safety findings Trial completion date: Feb 2022 --> Sep 2022 | Trial primary completion date: Feb 2022 --> Sep 2022
- |||||||||| LY3509754 / Eli Lilly, peresolimab (LY3462817) / Eli Lilly
Enrollment change, Trial termination: A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis (clinicaltrials.gov) - Mar 15, 2022
P1, N=30, Terminated,
Trial completion date: Feb 2022 --> Sep 2022 | Trial primary completion date: Feb 2022 --> Sep 2022 N=94 --> 30 | Active, not recruiting --> Terminated; Terminated due to liver findings
- |||||||||| LY3509754 / Eli Lilly, peresolimab (LY3462817) / Eli Lilly
Trial completion date, Trial primary completion date: A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis (clinicaltrials.gov) - Jan 19, 2022
P1, N=94, Suspended,
Suspended --> Active, not recruiting Trial completion date: Jul 2022 --> Mar 2022 | Trial primary completion date: Jul 2022 --> Mar 2022
- |||||||||| LY3509754 / Eli Lilly
Trial completion date, Trial suspension, Trial primary completion date: A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants (clinicaltrials.gov) - Dec 13, 2021
P1, N=105, Suspended,
Trial completion date: Jul 2022 --> Mar 2022 | Trial primary completion date: Jul 2022 --> Mar 2022 Trial completion date: Oct 2021 --> Feb 2022 | Active, not recruiting --> Suspended | Trial primary completion date: Oct 2021 --> Feb 2022
- |||||||||| LY3509754 / Eli Lilly, peresolimab (LY3462817) / Eli Lilly
Trial completion date, Trial primary completion date: A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis (clinicaltrials.gov) - Nov 18, 2021
P1, N=94, Suspended,
Trial completion date: Oct 2021 --> Feb 2022 | Active, not recruiting --> Suspended | Trial primary completion date: Oct 2021 --> Feb 2022 Trial completion date: Apr 2022 --> Jul 2022 | Trial primary completion date: Apr 2022 --> Jul 2022
- |||||||||| LY3509754 / Eli Lilly, peresolimab (LY3462817) / Eli Lilly
Trial completion date, Trial primary completion date: A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis (clinicaltrials.gov) - Jun 18, 2021
P1, N=64, Active, not recruiting,
Recruiting --> Active, not recruiting Trial completion date: Oct 2021 --> Apr 2022 | Trial primary completion date: Oct 2021 --> Apr 2022
- |||||||||| LY3509754 / Eli Lilly, peresolimab (LY3462817) / Eli Lilly
Enrollment closed, Trial completion date, Trial primary completion date: A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis (clinicaltrials.gov) - Mar 4, 2021
P1, N=64, Active, not recruiting,
Trial completion date: Oct 2021 --> Apr 2022 | Trial primary completion date: Oct 2021 --> Apr 2022 Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Oct 2021 | Trial primary completion date: Dec 2022 --> Oct 2021
- |||||||||| LY3509754 / Eli Lilly
Enrollment open: A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants (clinicaltrials.gov) - Oct 28, 2020
P1, N=121, Recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Oct 2021 | Trial primary completion date: Dec 2022 --> Oct 2021 Not yet recruiting --> Recruiting
- |||||||||| LY3509754 / Eli Lilly, peresolimab (LY3462817) / Eli Lilly
Trial completion date, Trial suspension, Trial primary completion date: A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis (clinicaltrials.gov) - Apr 21, 2020
P1, N=64, Suspended,
Suspended --> Recruiting Trial completion date: Sep 2022 --> Dec 2022 | Recruiting --> Suspended | Trial primary completion date: Sep 2022 --> Dec 2022
- |||||||||| LY3509754 / Eli Lilly, peresolimab (LY3462817) / Eli Lilly
Trial completion date, Trial primary completion date: A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis (clinicaltrials.gov) - Feb 19, 2020
P1, N=64, Recruiting,
Trial completion date: Sep 2022 --> Dec 2022 | Recruiting --> Suspended | Trial primary completion date: Sep 2022 --> Dec 2022 Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Jun 2021 --> Sep 2022
- |||||||||| LY3509754 / Eli Lilly, peresolimab (LY3462817) / Eli Lilly
Enrollment open, Trial completion date: A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis (clinicaltrials.gov) - Dec 3, 2019
P1, N=64, Recruiting,
Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Jun 2021 --> Sep 2022 Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Sep 2021
|
